Qiagen alleges that BioMérieux infringes a European patent that protects the company's QuantiFeron interferon-gamma release assay technology for latent TB detection.

Of the 30 companies on the list, 22 firms saw their share prices decline month over month, while eight companies saw their stock prices rise.

Last week, readers were most interested in a story about Pfizer shuttering the Lucira Health business that it acquired in 2023.

The firm's Anti-Measles Virus ELISA 2.0 (IgG) is used with dried blood spot samples to identify infections and determine patients' immune status.

The paper-based card separates plasma from whole-blood samples, allowing them to be used for HIV viral load testing.

NEW YORK – Investigators at Oregon Health and Science University have developed a novel and simple assay they say could improve screening and detection of pancreatic cancer among individuals with ...

NEW YORK — Dutch diagnostics firm MRC Holland said on Friday that two of its blood-based assays for spinal muscular atrophy (SMA) have been certified under Europe's In Vitro Diagnostic Regulation ...

One ACED project is focused on developing biomarkers for the early detection of ovarian cancer, with the goal of commercializing any resulting tests.

The company aims to soon launch two tests to aid the treatment of dermatomycosis and is developing other tests for healthcare ...